Neo on the Weekly Looking at #neo as it previously broke the rising wedge with a weekly triple top. if monthly support brakes in red we will have a continuation to the downside. floor levels marked.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.62 USD
−78.73 M USD
660.57 M USD
126.92 M
About NeoGenomics, Inc.
Sector
Industry
CEO
Anthony P. Zook
Website
Headquarters
Fort Myers
Founded
1998
FIGI
BBG000BKH263
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
No news here
Looks like there's nothing to report right now
Neo founder: Decentralized innovation is not a race, blockchain Coin World reported that Neo is a smart contract platform established in 2014. Da Hongfei, the founder of Neo, said that the protocol regards itself as a pragmatic participant and is committed to promoting a platform that relies on blockchain technology to meet its transaction needs. world. He added
NeoGenomics Inc 🧙NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogen
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
NEO5107997
NeoGenomics, Inc. 0.25% 15-JAN-2028Yield to maturity
6.13%
Maturity date
Jan 15, 2028
NEO4983005
NeoGenomics, Inc. 1.25% 01-MAY-2025Yield to maturity
5.18%
Maturity date
May 1, 2025
See all NEO bonds
Curated watchlists where NEO is featured.
Frequently Asked Questions
The current price of NEO is 8.78 USD — it has increased by 0.69% in the past 24 hours. Watch NeoGenomics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeoGenomics, Inc. stocks are traded under the ticker NEO.
NEO stock has fallen by −6.79% compared to the previous week, the month change is a −6.40% fall, over the last year NeoGenomics, Inc. has showed a −41.70% decrease.
We've gathered analysts' opinions on NeoGenomics, Inc. future price: according to them, NEO price has a max estimate of 26.00 USD and a min estimate of 15.00 USD. Watch NEO chart and read a more detailed NeoGenomics, Inc. stock forecast: see what analysts think of NeoGenomics, Inc. and suggest that you do with its stocks.
NEO stock is 10.52% volatile and has beta coefficient of 1.20. Track NeoGenomics, Inc. stock price on the chart and check out the list of the most volatile stocks — is NeoGenomics, Inc. there?
Today NeoGenomics, Inc. has the market capitalization of 1.13 B, it has decreased by −4.72% over the last week.
Yes, you can track NeoGenomics, Inc. financials in yearly and quarterly reports right on TradingView.
NeoGenomics, Inc. is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NEO earnings for the last quarter are 0.04 USD per share, whereas the estimation was 0.03 USD resulting in a 38.73% surprise. The estimated earnings for the next quarter are −0.01 USD per share. See more details about NeoGenomics, Inc. earnings.
NeoGenomics, Inc. revenue for the last quarter amounts to 172.00 M USD, despite the estimated figure of 173.19 M USD. In the next quarter, revenue is expected to reach 171.30 M USD.
NEO net income for the last quarter is −15.32 M USD, while the quarter before that showed −17.70 M USD of net income which accounts for 13.42% change. Track more NeoGenomics, Inc. financial stats to get the full picture.
No, NEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 5, 2025, the company has 2.2 K employees. See our rating of the largest employees — is NeoGenomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NeoGenomics, Inc. EBITDA is −11.50 M USD, and current EBITDA margin is 0.13%. See more stats in NeoGenomics, Inc. financial statements.
Like other stocks, NEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeoGenomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeoGenomics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeoGenomics, Inc. stock shows the sell signal. See more of NeoGenomics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.